Prognostic biomarkers in lung cancer patients in terms of long-term survival

Basit Öğe Kaydı
dc.authoridEngin Ulukaya / 0000-0003-4875-5472en_US
dc.authorscopusidEngin Ulukaya / 6602927353
dc.authorwosidEngin Ulukaya / K-5792-2018
dc.contributor.authorCoşkun, Belkıs Nihan
dc.contributor.authorDizdar, Oğuzhan Sıtkı
dc.contributor.authorKorkmaz, Seniz
dc.contributor.authorUlukaya, Engin
dc.contributor.authorEvrensel, Türkkan
dc.date.accessioned2021-06-28T06:10:18Z
dc.date.available2021-06-28T06:10:18Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroduction: We aimed to investigate the predictive effect of serum M30 and M65 antigens on long-term prognosis in patients with advanced stage lung cancer before and after the first dose of chemotherapy. Methods: Fourty eight patients with advanced stage lung cancer were included in the study. Demographic data and histopathological characteristics of the patients were recorded. Serum levels of M30 and M65 were studied in 48 patients before chemotherapy, and in 43 patients both before and 48 hours after chemotherapy. Long-term survival was evaluated using Kaplan-Meier curves. The effect of high or low M30, M65 levels and M30/M65 ratio on long-term survival was investigated. Results: The mean age of the patients at the time of diagnosis was 57.52 ± 9.38 years. Fourty six of the 48 patients were men. While M30 value before chemotherapy was 163.23 ± 112.30 U/l; It was measured as 249.74 ± 266.67 U/l 48 hours after chemotherapy (p<0.001). While M65 value before chemotherapy was 415.97 ± 214.63 U/l; It was 656.65 ± 394.15 U/l hours after chemotherapy (p<0.001). Median survival time was calculated as 17 (2-142) months. It was found that the long-term survival of the group with a low M30/M65 ratio before chemotherapy was statistically significantly longer. It was observed that the M30/M65 ratio, or M30 or M65 alone, measured 48 hours after chemotherapy had no predictive value for long-term survival. Conclusion: The M30/M65 ratio before chemotherapy may be a prognostic factor for long-term survival in patients with advanced lung cancer.en_US
dc.identifier.citationCOŞKUN, B. N. C., DİZDAR, O. S., KORKMAZ, Ş., ULUKAYA, E., & EVRENSEL, T. Prognostic biomarkers in lung cancer patients in terms of long-term survival. Turkish Journal of Internal Medicine, 3(Supplement 1), 20-22.en_US
dc.identifier.doi10.46310/tjim.875437en_US
dc.identifier.endpage22en_US
dc.identifier.issn2687-4245en_US
dc.identifier.issueSupplement 1en_US
dc.identifier.startpage20en_US
dc.identifier.urihttps://doi.org/10.46310/tjim.875437
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1847
dc.identifier.volume3en_US
dc.institutionauthorUlukaya, Engin
dc.language.isoenen_US
dc.publisherDergiParken_US
dc.relation.ispartofTurkish Journal of Internal Medicineen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLung Canceren_US
dc.subjectM30 And M65 Antigenen_US
dc.subjectNeoadjuvant Therapyen_US
dc.subjectLong-Term Prognosisen_US
dc.titlePrognostic biomarkers in lung cancer patients in terms of long-term survivalen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
127.pdf
Boyut:
284.03 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Temel Tıp Bilimleri Bölümü Makale Koleksiyonu